ClearBridge Investments’s Corcept Therapeutics CORT Stock Holding History

ClearBridge Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-507,354	Closed	-$17.7M	–	701
2025 Q4	$17.7M	Sell	507,354 -654,474	-56%	-$51.4M	0.01%	435
2025 Q3	$96.6M	Sell	1,161,828 -6,107	-0.5%	-$442K	0.07%	239
2025 Q2	$85.7M	Buy	1,167,935 +896,788	+331%	+$65M	0.07%	247
2025 Q1	$31M	Sell	271,147 -210,242	-44%	-$12.8M	0.03%	368
2024 Q4	$24.3M	Sell	481,389 -52,304	-10%	-$2.74M	0.02%	416
2024 Q3	$24.7M	Sell	533,693 -37,123	-7%	-$1.32M	0.02%	417
2024 Q2	$18.5M	Sell	570,816 -11,539	-2%	-$316K	0.02%	456
2024 Q1	$14.7M	Buy	+582,355	New	+$13.8M	0.01%	508
2019 Q4	–	Sell	-357	Closed	-$5K	–	1102
2019 Q3	$5K	Buy	+357	New	+$4.39K	﹤0.01%	1031

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

ClearBridge Investments's CORT Position: Q1 2026 in Review

ClearBridge Investments sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 507,354 shares — an estimated $17.7M sold.

ClearBridge Investments first reported a position in CORT in Q3 2019 and held it in 9 quarters. The position peaked at $96.6M in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

ClearBridge Investments reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
ClearBridge Investments sold 507,354 Corcept Therapeutics shares in Q1 2026, an estimated $17.7M.
ClearBridge Investments first reported a position in Corcept Therapeutics in Q3 2019 and held it in 9 quarters.
ClearBridge Investments's Corcept Therapeutics position peaked at $96.6M in Q3 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on ClearBridge Investments's 13F filing for Q1 2026, filed 13 May 2026.